Investors & Media

2010 News and Events

Date Title   07/28/10 The Medicines Company Reports Second Quarter 2010 Financial Results Top Line Growth, Development Portfolio Progress and Strong Net Operating Performance PARSIPPANY, NJ, Jul 28, 2010 (MARKETWIRE via COMTEX) --The Medicines Company (NASDAQ: MDCO) today announced its financial results for the second quarter of 2010. Financial highlights for the second quarter of 2010: -- Net revenue increased to $110.1 million for the second quarter from $104.2 million for the second quarter 2009. -- Angiomax U.S. sales increased to $104.4 million compare...  07/14/10 The Medicines Company to Announce Second Quarter 2010 Financial Results on Wednesday, July 28, 2010 Conference Call to Be Held at 8:30 a.m. Eastern Time PARSIPPANY, NJ, Jul 14, 2010 (MARKETWIRE via COMTEX) --The Medicines Company (NASDAQ: MDCO) has scheduled its quarterly conference call for Wednesday, July 28, 2010 at 8:30 a.m. Eastern Time to discuss second quarter 2010 financial results and operational developments. The conference call will be available via phone and webcast. The dial in information is listed below: Domestic Dial In: 866.362.5158 Int...  05/21/10 The Medicines Company Provides PTO Litigation Update PARSIPPANY, NJ, May 21, 2010 (MARKETWIRE via COMTEX) --The Medicines Company (NASDAQ: MDCO) today announced that the U.S. District Court for the Eastern District of Virginia issued an order in the Company's lawsuit against the U.S. Patent and Trademark Office (the "PTO"), the U.S. Food and Drug Administration and the U.S. Department of Health and Human Services. The Company's lawsuit is seeking to set aside the PTO's denial of the Company's Hatch-Waxman application to extend the principal ...  05/19/10 The Medicines Company to Participate in the 2010 Citi Global Health Care Conference PARSIPPANY, NJ, May 19, 2010 (MARKETWIRE via COMTEX) --The Medicines Company (NASDAQ: MDCO) will present at the 2010 Citi Global Health Care Conference on Wednesday , May 26th, in New York, beginning at 11am Eastern Time. Clive Meanwell, Chairman and Chief Executive Officer, will provide a company overview and outlook in the presentation. The session will be webcast with a link available at The Medicines Company's website http://www.themedicinescompany.com under "Events." About The Me...  05/05/10 The Medicines Company to Participate in the Bank of America Merrill Lynch 2010 Health Care Conference PARSIPPANY, NJ, May 05, 2010 (MARKETWIRE via COMTEX) --The Medicines Company (NASDAQ: MDCO) will present at the Bank of America Merrill Lynch 2010 Health Care Conference on Wednesday , May 12th, in New York, beginning at 3:40pm Eastern Time. Glenn Sblendorio, Executive Vice President and Chief Financial Officer, will provide a company overview and outlook in the presentation. The session will be webcast with a link available at The Medicines Company's website http://www.themedicinescompa...  04/29/10 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 PARSIPPANY, NJ, Apr 29, 2010 (MARKETWIRE via COMTEX) --The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to one new hire. The inducement stock options cover 5,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10-year term and vest over four years as follows: 25 percen...  04/28/10 The Medicines Company to Participate in the Deutsche Bank 35th Annual Health Care Conference PARSIPPANY, NJ, Apr 28, 2010 (MARKETWIRE via COMTEX) --The Medicines Company (NASDAQ: MDCO) will present at the Deutsche Bank 35th Annual Health Care Conference on Wednesday , May 5th, in Boston, beginning at 12:55pm Eastern Time. Glenn Sblendorio, Executive Vice President and Chief Financial Officer, will provide a company overview and outlook in the presentation. The session will be webcast with a link available at The Medicines Company's website http://www.themedicinescompany.com unde...  04/28/10 FOR U.S. AUDIENCES ONLY: The Medicines Company Reports First Quarter 2010 Financial Results Global Angiomax(R)/Angiox(R) (Bivalirudin) Hospital Demand Reaches Record High Revenue Gains and Cost Reductions Move Company to Profitability for Quarter PARSIPPANY, NJ, Apr 28, 2010 (MARKETWIRE via COMTEX) --The Medicines Company (NASDAQ: MDCO) today announced its financial results for the first quarter of 2010. Financial highlights: -- Net revenue increased to $102.1 million from $99.2 million for the same period 2009. -- Angiomax U.S. sales increased to $95.7 million...  04/21/10 FOR US AUDIENCES ONLY: The Medicines Company to Announce First Quarter 2010 Financial Results on Wednesday, April 28, 2010 Conference Call to Be Held at 8:30 a.m. Eastern Time PARSIPPANY, NJ, Apr 21, 2010 (MARKETWIRE via COMTEX) --The Medicines Company (NASDAQ: MDCO) has scheduled its quarterly conference call for Wednesday, April 28, 2010 at 8:30 a.m. Eastern Time to discuss first quarter 2010 financial results and operational developments. The conference call will be available via phone and webcast. The dial in information is listed below: Domestic Dial In: 888-396-2384 Interna...  03/26/10 The Medicines Company Files Follow Up PTO Lawsuit PARSIPPANY, NJ, Mar 26, 2010 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced that it filed a complaint against the U.S. Patent and Trademark Office (PTO), the U.S. Food and Drug Administration and the U.S. Department of Health and Human Services seeking to set aside the PTO's denial last week of the Company's Hatch-Waxman application to extend the principal U.S. patent covering Angiomax. This complaint, filed in the U.S. District Court for the Eastern District o...  03/19/10 The Medicines Company Provides Update on PTO Litigation PARSIPPANY, NJ, Mar 19, 2010 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today provided an update on actions by the U.S. Patent and Trademark Office (the "PTO") related to the Company's application pursuant to the Hatch-Waxman Act to extend the term of United States Patent No. 5,196,404 (the "'404 patent"), the principal U.S. patent that covers Angiomax. On March 16, 2010, the U.S. District Court for the Eastern District of Virginia set aside PTO's prior denial of The M...  03/17/10 The Medicines Company Expands a Nationwide Recall for Certain Lots of Cleviprex(R) That May Contain Particulate Matter For U.S. Audiences OnlyPARSIPPANY, NJ, Mar 17, 2010 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that it is voluntarily expanding the recall of Cleviprex (R) (clevidipine butyrate) injectable emulsion due to the potential presence of visible particulate matter which has been observed in some vials. Four (4) additional lots of Cleviprex are being recalled. The four additional Cleviprex lots are 68-407-DJ, Exp. 08/2010; 68-408-DJ, Exp. 08/2011; 71-101-DJ and 71-1...  03/16/10 The Medicines Company Announces Decision in PTO and FDA Litigation PARSIPPANY, NJ, Mar 16, 2010 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced that the U.S. District Court for the Eastern District of Virginia issued an order in the Company's lawsuit against the U.S. Patent and Trademark Office (the "PTO"), the U.S. Food and Drug Administration and the U.S. Department of Health and Human Services. The Company's lawsuit seeks to set aside the denial of the Company's application pursuant to the Hatch-Waxman Act to extend the ...  02/26/10 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 PARSIPPANY, NJ, Feb 26, 2010 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to one new hire. The inducement stock options cover 20,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10-year term and vest over four years as follows: 25 percent of...  02/17/10 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 PARSIPPANY, NJ, Feb 17, 2010 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to two new hires. The inducement stock options cover 20,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10-year term and vest over four years as follows: 25 percent o...  02/17/10 For U.S. Audiences Only: The Medicines Company Reports Full Year and Fourth Quarter 2009 Financial Results Revenue Growth Driven by Angiomax(R) (bivalirudin) Market Share Gains Product Portfolio Expanded From Existing Cash FlowPARSIPPANY, NJ, Feb 17, 2010 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced its financial results for the full year and the fourth quarter of 2009. Financial highlights for the full year of 2009: -- Net revenue increased by $56 million or 16.1% to $404.2 million for 2009 from $348.2 million in 2008. -- Angiomax U.S. sales incr...  02/09/10 For US Audiences Only: The Medicines Company to Announce Fourth Quarter and Full Year 2009 Financial Results on Wednesday, February 17, 2010 Conference Call to Be Held at 8:30 a.m. Eastern TimePARSIPPANY, NJ, Feb 09, 2010 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) has scheduled its quarterly conference call for Wednesday, February 17, 2010 at 8:30 a.m. Eastern Time to discuss fourth quarter and full year 2009 financial results, operational developments, and outlook for 2010. The conference call will be available via phone and webcast. The dial in information is listed below: Domestic Dial In: ...  01/15/10 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 PARSIPPANY, NJ, Jan 15, 2010 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to five new hires. The inducement stock options cover 6,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10-year term and vest over four years as follows: 25 percent o...  01/05/10 The Medicines Company to Participate in the 28th Annual JP Morgan Healthcare Conference PARSIPPANY, NJ, Jan 05, 2010 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) will present at the 28th Annual JP Morgan Healthcare Conference on Tuesday, January 12th, in San Francisco, beginning at 2:30pm Pacific Standard Time, 5:30pm Eastern Standard Time. Clive A. Meanwell, Chairman and Chief Executive Officer, will provide a company overview and outlook in the presentation. The session will be webcast with a link available at The Medicines Company's website http://www.themed...  01/04/10 The Medicines Company Files Additional Patent Infringement Lawsuits PARSIPPANY, NJ, Jan 04, 2010 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced that it has filed lawsuits against Teva Parenteral Medicines, Inc., Pliva Hrvatska d.o.o. and related entities in the United States District Court for the District of Delaware alleging patent infringement based on Abbreviated New Drug Applications seeking U.S. Food and Drug Administration approval to market and sell generic versions of The Medicines Company's Angiomax(R) product prior to ...